Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 1 |
Descriptor
| Adolescents | 1 |
| Attention Deficit Disorders | 1 |
| Autism | 1 |
| Behavior Problems | 1 |
| Children | 1 |
| Comparative Analysis | 1 |
| Drug Therapy | 1 |
| Hyperactivity | 1 |
| Outcomes of Treatment | 1 |
| Pervasive Developmental… | 1 |
| Pharmacology | 1 |
| More ▼ | |
Source
| Journal of the American… | 1 |
Author
| Aman, Michael G. | 1 |
| Arnold, L. Eugene | 1 |
| Cook, Amelia M. | 1 |
| Hall, Kristy L. | 1 |
| Ramadan, Yaser | 1 |
| Thompson, Susan | 1 |
| Witwer, Andrea N. | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 1 |
What Works Clearinghouse Rating
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Peer reviewed
Direct linkArnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
